Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment

Psychological Medicine

Volumn 43, Issue 5, 2013, Pages 911-920

  Ramakers, I H G B ^a   Verhey, F R J ^a   Scheltens, P ^b   Hampel, H ^c   Soininen, H ^d   Aalten, P ^a   Rikkert, M Olde ^e   Verbeek, M M ^e   Spiru, L ^f   Blennow, K ^g   Trojanowski, J Q ^h   Shaw, L M ^h   Visser, P J ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GOETHE UNIVERSITY   (Germany)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; anxiety; apathy; biomarkers; cerebrospinal fluid; depression; mild cognitive impairment; neuropsychiatric symptoms

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ANXIETY; APATHY; ARTICLE; CEREBROSPINAL FLUID; COHORT ANALYSIS; CONFIDENCE INTERVAL; DEPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IRRITABILITY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RISK;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANXIETY; APATHY; BIOLOGICAL MARKERS; COHORT STUDIES; CONFIDENCE INTERVALS; DEPRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IRRITABLE MOOD; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; ODDS RATIO; TAU PROTEINS;

EID: 84875937818     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291712001870     Document Type: Article

References (50)

1. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack Jr. CR, Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW (2010). Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimer's and Dementia 6, 239-246.
2. (1-42) in Alzheimer disease: differences between early-and late-onset Alzheimer disease and stability during the course of disease. Archives of Neurology 56, 673-680.
3. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn, revised. American Psychiatric Association: Washington, DC.
4. Apostolova LG, Cummings JL (2007). Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dementia and Other Geriatric Cognitive Disorders 25, 115-126.
5. Barnes LL, Schneider JA, Boyle PA, Bienias JL, Bennett DA (2006). Memory complaints are related to Alzheimer disease pathology in older persons. Neurology 67, 1581-1585.
6. Berlow YA, Wells WM, Ellison JM, Sung YH, Renshaw PF, Harper DG (2010). Neuropsychiatric correlates of white matter hyperintensities in Alzheimer's disease. International Journal of Geriatric Psychiatry 25, 780-788.
7. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H (2006). CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035-3041.
8. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
9. DeKosky ST (2008). Taking the next steps in the diagnosis of Alzheimer's disease: the use of biomarkers. CNS Spectrums 13, 7-10.
10. Devier DJ, Pelton GH, Tabert MH, Liu X, Cuasay K, Eisenstadt R, Marder K, Stern Y, Devanand DP (2009). The impact of anxiety on conversion from mild cognitive impairment to Alzheimer's disease. International Journal of Geriatric Psychiatry 24, 1335-1342.
11. Engelborghs S, Maertens K, Vloeberghs E, Aerts T, Somers N, Marien P, De Deyn PP (2006). Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochemistry International 48, 286-295.
12. 181 for identifying Alzheimer's disease amyloid plaque pathology. Archives of Neurology 68, 1137-1144.
13. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R (2007). Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurology 6, 501-512.
14. Folstein MF, Folstein SE, McHugh PR (1975). 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12, 189-198.
15. Gabryelewicz T, Styczynska M, Luczywek E, Barczak A, Pfeffer A, Androsiuk W, Chodakowska-Zebrowska M, Wasiak B, Peplonska B, Barcikowska M (2007). The rate of conversion of mild cognitive impairment to dementia: predictive role of depression. International Journal of Geriatric Psychiatry 22, 563-567.
16. Geda YE, Roberts RO, Knopman DS, Petersen RC, Christianson TJ, Pankratz VS, Smith GE, Boeve BF, Ivnik RJ, Tangalos EG, Rocca WA (2008). Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Archives of General Psychiatry 65, 1193-1198.
17. Gudmundsson P, Skoog I, Waern M, Blennow K, Palsson S, Rosengren L, Gustafson D (2007). The relationship between cerebrospinal fluid biomarkers and depression in elderly women. American Journal of Geriatric Psychiatry 15, 832-838.
18. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006). Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology 5, 228-234.
19. Lanari A, Amenta F, Silvestrelli G, Tomassoni D, Parnetti L (2006). Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mechanisms of Ageing Development 127, 158-165.
20. Landes AM, Sperry SD, Strauss ME, Geldmacher DS (2001). Apathy in Alzheimer's disease. Journal of the American Geriatric Society 49, 1700-1707.
21. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S (2002). Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA 288, 1475-1483.
22. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009). CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
23. Modrego PJ, Ferrandez J (2004). Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Archives of Neurology 61, 1290-1293.
24. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Toga AW, Beckett L (2005). The Alzheimer's disease neuroimaging initiative. Neuroimaging Clinics of North America 15, xi-xii.
25. 181) in cerebrospinal fluid by the xMAP technology. Clinical Chemistry 51, 336-345.
26. Palmer K, Berger AK, Monastero R, Winblad B, Backman L, Fratiglioni L (2007). Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology 68, 1596-1602.
27. Palmer K, Di Iulio F, Varsi AE, Gianni W, Sancesario G, Caltagirone C, Spalletta G (2010). Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer's disease: the role of depression and apathy. Journal of Alzheimer's Disease 20, 175-183.
28. Ramakers IH, Visser PJ, Aalten P, Kester A, Jolles J, Verhey FR (2010). Affective symptoms as predictors of Alzheimer's disease in subjects with mild cognitive impairment: a 10-year follow-up study. Psychological Medicine 40, 1193-1201.
29. 42 and tau proteins. Clinical Chemistry 53, 859-865.
30. Robert PH, Berr C, Volteau M, Bertogliati C, Benoit M, Sarazin M, Legrain S, Dubois B (2006). Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year follow-up study. Clinical Neurology and Neurosurgery 108, 733-736.
31. Rozzini L, Chilovi BV, Trabucchi M, Padovani A (2005). Depression is unrelated to conversion to dementia in patients with mild cognitive impairment. Archives of Neurology 62, 505.
32. Schmand B, Jonker C, Hooijer C, Lindeboom J (1996). Subjective memory complaints may announce dementia. Neurology 46, 121-125.
33. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009). Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology 65, 403-413.
34. Sierksma AS, van den Hove DL, Steinbusch HW, Prickaerts J (2010). Major depression, cognitive dysfunction and Alzheimer's disease: is there a link? European Journal of Pharmacology 626, 72-82.
35. Sinoff G, Werner P (2003). Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive decline. International Journal of Geriatric Psychiatry 18, 951-959.
36. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, Skoog I, Wallin A, Wahlund LO, Marcusson J, Nagga K, Andreasen N, Davidsson P, Vanmechelen E, Blennow K (2001). Tau and Ab42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clinical Chemistry 47, 1776-1781.
37. Skogseth R, Mulugeta E, Jones E, Ballard C, Rongve A, Nore S, Alves G, Aarsland D (2008). Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. Dementia and Other Geriatric Cognitive Disorders 25, 559-563.
38. Starkstein SE, Mizrahi R, Capizzano AA, Acion L, Brockman S, Power BD (2009). Neuroimaging correlates of apathy and depression in Alzheimer's disease. Journal of Neuropsychiatry and Clinincal Neurosciences 21, 259-265.
39. 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 2094-2103.
40. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009). Cerebrospinal fluid b-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Archives of Neurology 66, 382-389.
41. Teng E, Lu PH, Cummings JL (2007). Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 24, 253-259.
42. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jackv Jr. CR, Jagust W, Toga AW, Lee VM, Shaw LM (2010). Update on the Biomarker Core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's and Dementia 6, 230-238.
43. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009). Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurology 8, 619-627.
44. Visser PJ, Verhey FR, Boada M, Bullock R, De Deyn PP, Frisoni GB, Frolich L, Hampel H, Jolles J, Jones R, Minthon L, Nobili F, Olde Rikkert M, Ousset PJ, Rigaud AS, Scheltens P, Soininen H, Spiru L, Touchon J, Tsolaki M, Vellas B, Wahlund LO, Wilcock G, Winblad B (2008). Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study. Neuroepidemiology 30, 254-265.
45. Visser PJ, Verhey FR, Ponds RW, Kester A, Jolles J (2000). Distinction between preclinical Alzheimer's disease and depression. Journal of the American Geriatrics Society 48, 479-484.
46. Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der Flier W, Aalten P, Teunissen C, Barkhof F, Blennow K, Wolz R, Rueckert D, Verhey F, Visser PJ (2012). Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiology of Aging. Published online 19 January 2012. doi:10.1016/j.neurobiolaging. 2011.12.017.
47. Weiner MW, Aisen PS, Jack Jr. CR, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M (2010). The Alzheimer's Disease Neuroimaging Initiative: progress report and future plans. Alzheimer's and Dementia 6, 202-211.e7.
48. Wilson RS, Schneider JA, Bienias JL, Arnold SE, Evans DA, Bennett DA (2003). Depressive symptoms, clinical AD, and cortical plaques and tangles in older persons. Neurology 61, 1102-1107.
49. Wolz R, Aljabar P, Hajnal JV, Hammers A, Rueckert D (2010). LEAP: learning embeddings for atlas propagation. Neuroimage 49, 1316-1325.
50. Wuwongse S, Chang RC, Law AC (2010). The putative neurodegenerative links between depression and Alzheimer's disease. Progress in Neurobiology 91, 362-375.